Authors: Loucera C, Pena-Chilet M, Esteban-Medina M, Villegas R, Tunez I doi: https://doi.org/10.1101/2021.04.27.21255937 Abstract Background COVID-19 is a major worldwide health problem because of acute respiratory distress syndrome, and mortality. Several lines of evidence have suggested a relationship between the vitamin D endocrine system and severity of COVID-19. Methods We present a retrospective survival study [...]

Auhtors: Ciscato F, Ferrone L, Masgras I, Laquatra C, Rasola A PMID: 33946854 PMCID: PMC8125560 DOI: 10.3390/ijms22094716 Abstract Hexokinases are a family of ubiquitous exose-phosphorylating enzymes that prime glucose for intracellular utilization. Hexokinase 2 (HK2) is the most active isozyme of the family, mainly expressed in insulin-sensitive tissues. HK2 induction in most neoplastic cells contributes [...]

Authors: Chamie-Quintero JJ, Hibberd JA, Scheim DE doi: https://doi.org/10.5061/dryad.dv41ns1xr Abstract Objective. We aimed to identify mortality trends associated with COVID-19 deaths in Peru during April through November 2020, when mass treatments with ivermectin (IVM), a drug of Nobel Prize-honored distinction, were autonomously deployed at different times and to different extents in [...]

Auhtors: Talib WH, Alsayed AR, Abuawad A, Daoud S, Mahmod AI PMID: 33923028 PMCID: PMC8123278 DOI: 10.3390/molecules26092506 Abstract Melatonin is a pleotropic molecule with numerous biological activities. Epidemiological and experimental studies have documented that melatonin could inhibit different types of cancer in vitro and in vivo. Results showed the involvement of melatonin in different anticancer [...]

Authors: Kory P, Meduri GU, Iglesias J, Varon J, Berkowitz K, Wagshul F et al. PMID: 34375047 doi: 10.1097/MJT.0000000000001377 PMCID: PMC8088823 Abstract Background: After COVID-19 emerged on U.S shores, providers began reviewing the emerging basic science, translational, and clinical data to identify potentially effective treatment options. In addition, a multitude of both novel and repurposed [...]

Authors: Kory P, Meduri GU, Iglesias J, Varon J, Berkowitz K, Wagshul F et al. PMID: 34375047 PMCID: PMC8088823 DOI: 10.1097/MJT.0000000000001377 Abstract Background: After COVID-19 emerged on U.S shores, providers began reviewing the emerging basic science, translational, and clinical data to identify potentially effective treatment options. In addition, a multitude of both novel and repurposed [...]

Authors: Al-Aly Z, Xie Y, Bowe B PMID: 33887749 DOI: 10.1038/s41586-021-03553-9 Abstract The acute clinical manifestations of COVID-19 have been well characterized1,2, but the post-acute sequelae of this disease have not been comprehensively described. Here we use the national healthcare databases of the US Department of Veterans Affairs to systematically and comprehensively identify 6-month incident [...]

Authors: Lavinio A, Ercole A, Battaglini D, Magnoni S, Badenes R, Thomas W et al. PMID: 33888132 PMCID: PMC8061459 DOI: 10.1186/s13054-021-03543-3 Abstract Introduction: Critical illness from SARS-CoV-2 infection (COVID-19) is associated with a high burden of pulmonary embolism (PE) and thromboembolic events despite standard thromboprophylaxis. Available guidance is discordant, ranging from standard care to the [...]

After COVID-19 emerged on U.S shores, providers began reviewing the emerging basic science, translational, and clinical data to identify potentially effective treatment options. In addition, a multitude of both novel and repurposed therapeutic agents were used empirically and studied within clinical trials.

Authors: Sukhatme VP, Reiersen AM, Vayttaden SJ, Sukhatme VV doi: https://doi.org/10.3389/fphar.2021.652688 Abstract Fluvoxamine is a well-tolerated, widely available, inexpensive selective serotonin reuptake inhibitor that has been shown in a small, double-blind, placebo-controlled, randomized study to prevent clinical deterioration of patients with mild coronavirus disease 2019 (COVID-19). Fluvoxamine is also an agonist for the sigma-1 receptor, [...]